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AbstrACt
Objectives this study aimed to develop consensus 
on an internationally agreed dataset for juvenile 
dermatomyositis (JdM), designed for clinical use, to 
enhance collaborative research and allow integration of 
data between centres.
Methods A prototype dataset was developed 
through a formal process that included analysing items 
within existing databases of patients with idiopathic 
inflammatory myopathies. this template was used to aid 
a structured multistage consensus process. Exploiting 
delphi methodology, two web-based questionnaires 
were distributed to healthcare professionals caring for 
patients with JdM identified through email distribution 
lists of international paediatric rheumatology and 
myositis research groups. A separate questionnaire was 
sent to parents of children with JdM and patients with 
JdM, identified through established research networks 
and patient support groups. the results of these parallel 
processes informed a face-to-face nominal group 
consensus meeting of international myositis experts, 
tasked with defining the content of the dataset. this 
developed dataset was tested in routine clinical practice 
before review and finalisation.
results A dataset containing 123 items was formulated 
with an accompanying glossary. demographic and 
diagnostic data are contained within form A collected at 
baseline visit only, disease activity measures are included 
within form B collected at every visit and disease damage 
items within form C collected at baseline and annual 
visits thereafter.
Conclusions through a robust international process, 
a consensus dataset for JdM has been formulated that 
can capture disease activity and damage over time. 
this dataset can be incorporated into national and 
international collaborative efforts, including existing 
clinical research databases.
IntrOduCtIOn
Juvenile dermatomyositis (JDM) is associated with 
significant morbidity and mortality.1–3 To better 
understand this rare disease,4 international collab-
oration is essential. This is feasible with the devel-
opment of national and international electronic 
web-based registries and biorepositories.5 6 For 
good clinical care and to aid comparison of data 
between groups, it is crucial to have a common 
dataset that clinicians and researchers collect in 
a standardised way, with items clearly defined. 
The International Myositis and Clinical Studies 
(IMACS) Group7–9 and Paediatric Rheumatology 
International Trials Organisation (PRINTO)10–12 
JDM core sets were developed predominantly for 
research studies. Existing myositis registries include 
partially overlapping but different dataset items, 
making comparison between groups challenging.13 
This study aimed to define optimal items from 
existing datasets that would be useful to collect in 
routine practice, within accessible disease-specific 
registries, that, when measured over time, would 
help capture disease outcome/treatment response, 
which would facilitate both patient care and trans-
lational research.
MethOds
The study protocol and background work have been 
published.13 14 The study is registered on the Core 
Outcome Measures in Effectiveness Trials initiative 
database.15 The Core Outcome Set—STAndards for 
Reporting standards for reporting were followed.16 
The study overview is shown in figure 1.
background work
A steering committee (SC) developed a prototype 
dataset by scrutinising all items within existing 
international databases of juvenile-onset myositis 
(JM) and adult-onset myositis,1 17–19 informed by 
a literature search and detailed analysis of the UK 
Juvenile Dermatomyositis Cohort Biomarker Study 
and Repository (JDCBS).13 19 Leading representa-
tives of each partner organisation9 12 17 20 21 detailed 
in the study protocol14 approved the template/
provisional dataset.
stakeholder groups
This study design aimed to employ representation 
from healthcare professionals with experience 
in myositis working as physicians, allied health 
professionals or clinical scientists in paediatric or 
adult medicine within rheumatology, neurology or 
dermatology14 and consumers (patients with JM 
and their parents or carers).
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healthcare professional delphi process
A two-stage Delphi process was undertaken.14 Items contained 
within the prototype dataset were listed and further modified 
by the SC to ensure clarity. The items were formatted into a 
custom-made electronic questionnaire, piloted before distri-
bution. After modifications, the Delphi template included 70 
items with an additional 53 conditional on previous response 
(detailed in online supplementary table S1). Participation was 
invited via membership lists of IMACS, Childhood Arthritis and 
Rheumatology Research Alliance (CARRA), Juvenile Dermato-
myositis Research Group (JDRG) UK and Ireland, Paediatric 
Rheumatology European Society (PReS) JDM working party and 
PRINTO Centre Directors. These are representative of interna-
tional paediatric rheumatology and myositis specialty groups, 
capturing opinion of clinicians, scientists and allied health 
professionals. The estimated membership of these groups totals 
more than 1000. However, the majority of members belong 
to more than one organisation and membership lists include 
retired/non-active members or specialists working in adult-onset 
myositis potentially less inclined to answer a paediatric-specific 
survey.14 Participants were asked to rate the importance of each 
item for clinical practice and separately for value in research, 
using a scale of 1–9: 1–3 (of low importance), 4–6 (important 
but not critical) and 7–9 (critical).14 An option of ‘unable to 
score’ was given and free text comments were allowed. Delphi 
2 was sent to participants who scored 75% or more of the items 
in round 1 of the Delphi. Each participant was asked to re-score 
each item, having been shown the distribution of scores for the 
group as a whole and their own score.
Patient and parent survey
The healthcare professionals’ survey was modified into separate 
parent and patient questionnaires as per protocol,14 formatted 
for computer or paper format completion. The questionnaires 
and age-appropriate information leaflets were reviewed by 
patient and public involvement coordinators and by parent/
young people’s focus groups.14 The focus groups also reviewed 
patient/parent-reported outcome measures (PROMs) used 
for JDM and other rheumatology conditions,22–27 and opin-
ions were summarised (online supplementary table S2). Thirty 
items were included in patient/parent questionnaires; 23 from 
adaptation of the Delphi (combining or simplifying items from 
the healthcare professional questionnaire and selecting items 
Figure 1 Flow chart showing study overview.
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particularly relevant to patients/parents), 2 additional questions 
added by the SC to determine patient/parent perspectives on 
collecting and storing information, plus 5 questions suggested 
by patients/parents within focus groups (online supplementary 
table S1). The scoring system was simplified into three categories 
of ‘not that important’, ‘important’ and ‘really important’. An 
option of ‘unable to score’ was given and free text comments 
were allowed. Participation was open to any patient with JM—
child/adult, or any parent/carer of a child with JM. Patients with 
adult-onset myositis (onset ≥18 years) were excluded. Informa-
tion leaflets and questionnaires were in English only; translators 
could be used if available. Patients/parents were signposted to 
the study via email distribution lists/websites of North American 
and UK patient support groups (Cure JM and Myositis UK),28 29 
the lead of the JDRG patient/parent groups and JDRG coordi-
nator.20 In addition, following site-specific ethics approval, UK 
centres participating in the JDCBS19 30 and a Netherlands site 
invited patients/parents to participate.
data analysis
For each item, the number and percentage of participants who 
scored the item and the distribution of scores (grades 1–9) were 
summarised for each stakeholder group. Consensus definitions 
were applied as ‘consensus in’ versus ‘equivocal’ or ‘consensus 
out’ according to predefined consensus definitions (table 1).
Consensus meeting
Eighteen voting delegates were invited to a 2-day consensus 
meeting, led by a non-voting facilitator (MWB). International 
representatives were experts in myositis from paediatric rheuma-
tology/myositis groups and professionals who care for patients 
with myositis including neurologists, dermatologists, adult 
rheumatologists and physiotherapists. Prior to the meeting, 
delegates were sent a summary of results to review. During the 
consensus meeting, Delphi 2 results and patient/parent results 
were presented for each item—as shown in online supplemen-
tary figure 1. Items achieving ‘consensus in’ within the Delphi 
and patient/parent questionnaires were voted on immediately. 
Those not achieving ‘consensus in’ were discussed by nominal 
group technique. Consensus was defined a priori as ≥80% 
(table 1). Discussion and re-voting allowed refinement of items 
or associated definitions. The process continued until consensus 
was reached or until it was clear that consensus would not be 
reached.
testing in practice
The proposed dataset was formatted into three sections (forms 
A, B and C) and tested in clinical practice. Members of the 
expert group were asked to test the dataset themselves and/
or delegate a member of their department unfamiliar with the 
dataset. Clinicians completed patient-anonymised data on one 
to two patients under their care and a feasibility questionnaire 
(online supplementary table S3). Feedback was considered 
by the SC and refinements made. The dataset was sent to the 
expert group, including representatives of partner organisations 
(IMACS, CARRA, PRINTO, PReS JDM working group, JDRG, 
Euromyositis) for comment.
results
Two hundred and sixty-two healthcare professionals accessed 
the system (26% of the estimated total membership of specialty 
groups). 181/262 (69%) completed ≥75% of Delphi 1 (June–
September 2014). One hundred and sixty-five agreed to take part 
in Delphi 2 (November 2014–January 2015); from these, 146 
replies were received (12% attrition). One hundred and seven-
ty-two participants provided full demographic data in round 
1 showing that survey responses were received from Europe 
(44%), North America (34%), Latin America (12%), Asia (6%), 
Australia/Oceania (0.5%), Middle East (3%) and Africa (0.5%). 
Respondents primarily were paediatric or adult rheumatologists 
(85%) or had an interest in rheumatology (8%), but also included 
clinical academics (specialty not defined, 4%), dermatologists 
(0.5%), neurologists (0.5%), physiotherapists (1%) or other 
professionals (1%). The majority of respondents had substan-
tial experience in the specialty (74% with ≥10 years of experi-
ence) and worked within paediatrics/mainly paediatrics (82.5% 
vs 17.5% of respondents working with adults). Responses were 
summarised as percentages of participants ranking items as 
critical for decision-making (score 7–9) for each item (clinical/
research), shown in online supplementary table S1. Availability 
of investigations to clinicians within clinical practice was also 
summarised from responses received in Delphi 1 (online supple-
mentary table S4 and online supplementary figure S1).
Patient/parent surveys
In total, 301 surveys were completed (198 from parents, 103 
patients). To allow time for sufficient data capture for parent/
patient questionnaires, data collection continued after the 
consensus meeting. At the consensus meeting, data were avail-
able from 16 completed patient surveys and 22 parent surveys. 
Decisions made at the consensus meeting with 38 responses still 
held true in the final analysis of 301 replies. Responses were 
received from Europe (53%), North America (44%) and other 
continents (3%). Patients completing the questionnaire were a 
median of 15 years of age (IQR 12–17). Parents completed ques-
tionnaires for children who had a median age of 11 years (IQR 
7–15). Overall, there was good agreement between patient/
parent surveys and the healthcare professionals’ Delphi and 
items agreed at the consensus meeting (online supplementary 
table S1). Key exceptions are summarised in table 2.
table 1 Definition of consensus for each stage of the study (defined a priori)
Consensus 
classification description
definition of consensus
healthcare professionals’ delphi Patient/parent survey Consensus meeting*
Consensus in Consensus that outcome should be 
included in core set
≥70% of participants scoring ‘7–9’ 
‘critical for decision-making’
≥70% of participants scoring ‘really 
important’
≥80% of participants voting for 
inclusion in core outcome set
Consensus out Consensus that outcome should not be 
included in the core outcome set
≥70% of participants scoring ‘1–3’ 
‘low importance’
≥70% of participants scoring ‘not that 
important’
<80% of participants voting for 
inclusion in core outcome set
Equivocal Uncertainty about importance of 
outcome
All other responses All other responses Further discussion by NGT and re-
voting allowed
*More stringent consensus cut-off for consensus meeting.
NGT, nominal group technique.
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Consensus meeting and output
All invited experts (n=18) attended the consensus meeting 
(Liverpool, March 2015), representing Europe (n=10), North 
America (n=6), Latin America (n=1) and Asia (n=1). Specialties 
included paediatric rheumatology (n=13), adult rheumatology 
(n=2), paediatric dermatology (n=1), paediatric neurology 
(n=1) and physiotherapy (n=1). Parents/patients were not 
included. Output from the consensus meeting is shown in online 
supplementary table S1. A set of recommendations for first 
visit, for each visit and for annual assessment was made. Refine-
ment took place following the consensus meeting via three 
rounds of SurveyMonkey, principally to better define myositis 
overlap features and disease damage items (shown in online 
supplementary table S1), with the same members of the expert 
group (100% response rate).
testing the dataset in practice
Glossaries of definitions/instructions to aid completion, along 
with muscle strength-testing sheets, were formulated into 
appendices, approved by the SC. Twenty clinicians tested the 
dataset (October 2016–April 2017); eight were present at the 
consensus meeting, three had completed the Delphi and nine 
were new to the dataset. Time taken to complete the dataset in 
clinical practice ranged from 5 to 45 min (median time 15 min). 
table 3 Summary of items included in the JDM optimal dataset, form A (completed at first/baseline visit only)
section heading Items
Additional items conditional on previous response 
(summary)
Personal factors/
demographics
1 Date of birth (year and month of birth±day of birth)
2 Sex of patient
Diagnostic factors 3 Date (year and month) of first symptom of myositis
4 Date (year and month) of diagnosis of JDM
5 At the time of diagnosis did the patient have proximal muscle weakness?
6 At the time of diagnosis did the patient have typical skin features of JDM 
(Gottron’s/heliotrope)?
7 Was an MRI scan done at diagnosis? Choice of options for MRI result (four options)
8 Was a muscle biopsy done at diagnosis? Choice of options for biopsy result (four options plus total 
biopsy score if available)
9 Were myositis-specific antibodies tested at diagnosis? If positive, asked to select all that apply (eight options)
10 Were myositis-associated antibodies tested at diagnosis? If positive, asked to select all that apply (nine options)
Treatments received prior to 
diagnosis of JDM
11 Did this patient receive systemic glucocorticoid prior to diagnosis of JDM? If yes, asked to select all that apply (three options)
12 Did this patient receive any synthetic or biologic disease modifying anti-
rheumatic drug prior to the diagnosis of JDM?
If yes, asked to select all that apply (13 options)
JDM, juvenile dermatomyositis.
table 2 Key differences between opinions of patients/parents and healthcare professionals
Item
Patients’ 
opinion Parents’ opinion
healthcare 
professionals’ 
opinion
Outcome from 
consensus 
meeting Comments/reasons for retaining in dataset
Raynaud’s phenomenon Equivocal Equivocal Consensus in Consensus in Important for overlap phenotypes especially 
myositis–scleroderma
Use of an age-appropriate patient/
parent measure of function
Equivocal Equivocal Consensus in Consensus in Retained (with the option of using alternative tools 
to allow for country-specific requirements) since 
these are standard outcome measures for research 
in JDM
Use of an age-appropriate patient/
parent measure of quality of life
Equivocal Equivocal Consensus in Consensus in
Parent/patient global assessment VAS Equivocal Equivocal Consensus in Consensus in
Physician global assessment VAS Equivocal Equivocal Consensus in Consensus in
Fatigue due to myositis (within PROM) Equivocal Consensus in Consensus in Consensus in—as 
part of a PROM
Quantifiable outcome measure
Questions related to physiotherapy Equivocal Equivocal Consensus in Consensus in Increasingly a defined therapeutic intervention; 
omitting would be akin to not asking about 
medicines
Pubertal assessment Equivocal Equivocal (Not asked)* Consensus in Important outcomes of disease activity/damage/
adverse effects of medicationHeight of patient Equivocal Consensus in Consensus in Consensus in
Weight of patient Equivocal Consensus in Consensus in Consensus in
Items related to major organ involvement—
cardiac/pulmonary/gastrointestinal
Equivocal Consensus in Consensus in Consensus in Important implications for disease severity, 
treatment and prognosis
Specific questions about pain Consensus in Consensus in (Not asked) Consensus out Thought to be part of standard care (questions that 
would be asked by a clinician in a clinic consultation)Specific questions about medicines Consensus in Consensus in (Not asked) Consensus out
Irritability due to JDM Equivocal Consensus in (Not asked) Consensus out Too non-specific and variable interpretation in 
different countries
*Added to patient/parent questionnaire after discussion in patient/parent focus groups.
JDM, juvenile dermatomyositis; PROM, patient/parent-reported outcome measure; VAS, Visual Analogue Scale.
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table 4 Summary of items included in the JDM optimal dataset, form B (completed at every visit representing status of the patient at the current 
time point)
section heading Items
Additional items conditional on previous 
response (summary)
Growth 1 Height of patient (in centimetres)
2 Weight of patient (in kilograms)
Muscular involvement 3 Presence of symmetrical proximal muscle weakness
4 Childhood Myositis Assessment Scale score State score (out of 52)
5 Manual Muscle Testing score State score (out of 80)
6 VAS score for global muscle disease activity If measured, mark score on 10 cm line*
Skeletal involvement 7 Arthritis due to myositis
8 Joint contractures due to myositis
9 VAS score for global skeletal disease activity If measured, mark score on 10 cm line*
Cutaneous involvement 10 Gottron’s papules or Gottron’s sign
11 Heliotrope rash
12 Periungual capillary loop changes (plus measure of capillary density if available)
13 Malar or facial erythema
14 Linear extensor erythema
15 ‘V’ sign
16 Shawl sign
17 Non sun-exposed erythema
18 Extensive cutaneous erythema, which may include erythroderma
19 Livedo reticularis
20 Cutaneous ulceration
21 Mucus membrane lesions
22 Mechanic’s hands
23 Cuticular overgrowth
24 Subcutaneous oedema
25 Panniculitis
26 Alopecia (non-scarring)
27 Calcinosis (with active disease)
28 VAS score for global cutaneous disease activity If measured, mark score on 10 cm line*
Features suggestive of 
myositis overlap
29 Does this patient have a myositis overlap condition? If yes, asked to select all that apply (four options)
30 Raynaud’s phenomenon
31 Sclerodactyly
Gastrointestinal involvement 32 Dysphagia due to myositis
33 Abdominal pain due to myositis
34 Gastrointestinal ulceration due to myositis
35 VAS score for global gastrointestinal disease activity If measured, mark score on 10 cm line*
Pulmonary involvement 36 Pulmonary involvement/respiratory muscle weakness or interstitial lung disease due to 
myositis
37 Dysphonia due to myositis
38 VAS score for global pulmonary disease activity If measured, mark score on 10 cm line*
Cardiovascular involvement 39 Cardiovascular involvement due to myositis
40 BP recording State systolic and diastolic measurement
41 BP elevated suggesting hypertension (for age of patient)
42 VAS score for global cardiovascular disease activity If measured, mark score on 10 cm line*
Constitutional features 43 Fever (>38°C) due to myositis
44 Weight loss (>5%) due to myositis
45 Fatigue due to myositis
46 VAS score for global constitutional disease activity If measured, mark score on 10 cm line*
Global disease assessment 
by clinician
47 Physician VAS score of global disease activity If measured, mark score on 10 cm line*
48 Physician VAS score of extramuscular disease activity If measured, mark score on 10 cm line*
Global disease assessment 
by patient/parent
49 Patient/parent VAS score for global disease activity If measured, mark score on 10 cm line* and state 
who completed (four options)
50 Patient/parent VAS score for pain If measured, mark score on 10 cm line*
PROM 51 Use of an age-appropriate PROM of function Asked to state PROM used and score
52 Use of an age-appropriate patient/parent-reported measure of quality of life Asked to state PROM used and score
Continued
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In addition, 15/20 (75%) found the dataset helpful in practice. 
Feedback was reviewed in detail by the SC and refinements 
made.
Completed optimal dataset
The resulting optimal dataset is summarised within tables 3–5 
representing three forms. They consist of 123 items: 12 (plus 6 
items conditional on responses to the initial 12) within form A, to 
be completed at first/baseline data entry only; 56 (plus 20 condi-
tional on responses to the 56) within form B, to be completed at 
every clinic visit representing status of the patient at the current 
time point; and 55 (plus 15 conditional on responses to the 55) 
within form C, to be completed at baseline and then annually to 
capture disease damage. The complete dataset with glossary of 
definitions and muscle strength-testing sheets can be found in 
the website of University of Liverpool (http:// ctrc. liv. ac. uk/ 
JDM/) and online supplementary table S5.
dIsCussIOn 
An internationally agreed JDM dataset has been designed for 
use within a clinical setting, with the potential to significantly 
enhance research collaboration and allow effective communica-
tion between groups. The accompanying glossary of definitions 
may be particularly helpful to those in training or physicians less 
familiar with JDM and for standardisation of the information. 
Key items are included within the dataset that allow documen-
tation of disease activity and damage with the ability to measure 
change over time. If adopted widely, the dataset could enable 
analysis of the largest possible number of patients with JDM 
to improve disease understanding. It is anticipated that further 
ratification of the dataset will take place when incorporated 
into existing registries and national/international collaborative 
research efforts. It is acknowledged that updates may be needed 
in the future to incorporate advances in JDM.
When tested in practice by a small number of clinicians, the 
forms took between 5 and 45 min to complete. The wide range 
is likely to be due to some respondents interpreting this question 
as time taken to complete the actual forms, while others may 
have documented time taken to complete all the tasks within the 
forms, including clinical examination. It is likely that comple-
tion time will be reduced as clinicians become familiar with the 
questions over time and employment of electronic data entry 
systems. The dataset does not encompass every aspect of a clinic 
consultation. Other factors such as adverse effects to medication 
or details of pain (ranked important by patients/parents) should 
be covered as part of standard care.
This study has benefited from the enormous contribution of 
patients and parents. It is interesting that patients do not neces-
sarily perceive items such as shortness of breath, chest pain and 
abdominal symptoms as important in JDM whereas for clini-
cians, major organ involvement has important implications for 
prognosis and treatment choices.31–37 Likewise, growth and 
pubertal parameters were rated less important by patients/
parents but retained due to impact of active disease and corti-
costeroid treatment on growth.38 39 Self-assessment is allowable 
to make pubertal assessment more acceptable to patients.40 
Notable discrepancies in healthcare professional and patient/
parent opinion included the use of PROMs capturing func-
tion and health-related quality of life (HRQOL). The benefits 
and limitations of individual tools have been described.22 27 
Within this study, comments from patient/parent surveys and 
focus groups suggested a dislike of 0–10 cm scales used in VAS 
measurements (data not shown). It is possible that a pain/general 
VAS is not adequate to capture the complexity of pain or overall 
feelings for a patient, particularly due to the variability of the 
disease. Despite this caveat, clinicians recognise the need to have 
outcome-driven data that include measures of activity, participa-
tion, pain and HRQOL.27 Patients with JDM have been found 
to have significant impairment in their HRQOL compared with 
healthy peers.41 PROMs used within the IMACS and PRINTO 
core sets, including the Childhood Health Assessment Question-
naire and Child Health Questionnaire, are not designed specif-
ically for JDM but have been evaluated and endorsed for use 
in juvenile myositis.22 The Juvenile Dermatomyositis Multidi-
mensional Assessment Report (JDMAR) is a multifunctional tool 
that includes function, quality of life, fatigue and adverse effects 
of medications that has been specifically developed for JDM.23 
It is currently undergoing further validation. Fatigue, rated as 
important by parents in this work, is included within the JDMAR. 
During the consensus meeting, it was not possible to define a 
single agreed PROM for function (activity) or HRQOL (partici-
pation) despite taking into consideration results of the healthcare 
professionals’ Delphi, patient/parent surveys and feedback from 
patients within a UK focus group (online supplementary table 
S2). The difficulty of PROMs being internationally accepted was 
discussed and noted. Specifically, items within tools developed 
in Europe/North America may not be relevant in economically 
less developed countries. It was agreed that the dataset would 
include a recommendation to use ‘an age-appropriate patient/
section heading Items
Additional items conditional on previous 
response (summary)
Investigations 53 Elevation of any muscle enzyme (including CPK, LDH, aldolase, AST/SGOT, ALT/SGPT) above 
normal range
If elevated, asked to select which apply (five 
options)
Specimens available 54 Has this patient had specimens taken that may be available for specific research projects? 
This may include DNA, serum, biomarkers, biopsy tissue or other material
If answer is ‘yes’, asked to select which apply 
(three options)
Treatment 55 Is the patient on treatment (now or since last visit)? Asked to select all that apply (16 options) and 
to state dose, route and frequency for each 
medication
56 Is the patient doing a regular exercise routine prescribed by a healthcare professional 
aimed at improving/maintaining:
(A) range of movement?
(B) muscle strength?
*0 is inactive or lowest score and 10 is most active or highest score on 10 cm VAS scores.
ALT, alanine transaminase; AST, aspartate aminotransferase; BP, blood pressure; CPK, creatine phosphokinase; JDM, juvenile dermatomyositis; LDH, lactate dehydrogenase; PROM, 
patient/parent-reported outcome measure; SGOT, serum glutamic oxaloacetic Transaminase; SGPT, serum glutamic-pyruvic transaminase; VAS, Visual Analogue Scale.
table 4 Continued 
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table 5 Summary of items included in the JDM optimal dataset, form C (completed at baseline visit and then annual visits only)
section heading Items
Additional items conditional on 
previous response (summary)
Muscular damage items 1 Muscle atrophy (clinical)
2 Muscle weakness not attributable to active muscle disease
3 Muscle dysfunction: decrease in aerobic exercise capacity
4 VAS for global muscle disease damage Mark score on 10 cm line*
Skeletal damage items 5 Joint contractures (due to myositis)
6 Osteoporosis with fracture or vertebral collapse (excluding avascular necrosis)
7 Avascular necrosis
8 Deforming arthropathy
9 VAS for global skeletal disease damage Mark score on 10 cm line*
Cutaneous damage items 10 Calcinosis (persistent)
11 Alopecia (scarring)
12 Cutaneous scarring or atrophy (depressed scar or cutaneous atrophy)
13 Poikiloderma
14 Lipoatrophy/lipodystrophy
15 VAS for global cutaneous disease damage Mark score on 10 cm line*
Gastrointestinal damage items 16 Dysphagia (persistent)
17 Gastrointestinal dysmotility, constipation, diarrhoea or abdominal pain (persistent)
18 Infarction or resection of bowel or other gastrointestinal organs
19 VAS for global gastrointestinal disease damage Mark score on 10 cm line*
Pulmonary damage items 20 Dysphonia (persistent)
21 Impaired lung function due to respiratory muscle damage
22 Pulmonary fibrosis
23 Pulmonary hypertension
24 VAS for global pulmonary disease damage Mark score on 10 cm line*
Cardiovascular damage items 25 Hypertension requiring treatment for >6 months
26 Ventricular dysfunction or cardiomyopathy
27 Assessed in adults (>18 years of age) only: angina or coronary artery bypass
28 Assessed in adults (>18 years of age) only: myocardial infarction
29 VAS for global cardiovascular damage Mark score on 10 cm line*
Peripheral vascular damage items 30 Tissue or pulp loss
31 Digit loss or limb loss or resection
32 Venous or arterial thrombosis with swelling, ulceration or venous stasis
33 Assessed in adults (>18 years of age) only: claudication
34 VAS for global peripheral vascular disease damage Mark score on 10 cm line*
Pubertal status of patient 35 Pubertal assessment completed by physician or by patient (self-assessment) Tanner score (1–5)
Endocrine damage items 36 Growth failure
37 Delay in development of secondary sexual characteristics (>2 SD beyond mean for age)
38 Hirsutism or hypertrichosis
39 Irregular menses
40 Primary or secondary amenorrhoea
41 Diabetes mellitus
42 In adults (>18 years of age): infertility—male or female
43 In adults (>18 years of age): sexual dysfunction
44 VAS for global endocrine disease damage Mark score on 10 cm line*
Ocular damage items 45 Cataract resulting in visual loss
46 Visual loss, other, not secondary to cataract
47 VAS for global ocular disease damage Mark score on 10 cm line*
Infection damage items 48 Chronic infection
49 Multiple infections
50 VAS for global infection damage Mark score on 10 cm line*
Malignancy 51 Presence of malignancy
52 VAS for malignancy (complications) Mark score on 10 cm line*
Other damage 53 Death Include cause and date of death
54 VAS for any other damage Mark score on 10 cm line* and add details 
of other damage
Global disease assessment damage 55 Physician VAS of global disease damage Mark score on 10 cm line*
*0 is inactive or lowest score and 10 is most active or highest score on 10 cm VAS scores.
JDM, juvenile dermatomyositis; VAS, Visual Analogue Scale.
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parent-reported outcome of function’  and ‘an age-appropriate 
patient/parent-reported measure of quality of life’. More work 
is needed to make PROMs acceptable to patients/parents and 
applicable to their disease.42 43
This study is limited by the fact that patient/parent ques-
tionnaires were available in English only, reducing the number 
of countries that could contribute; hence, there is low patient 
participation outside of Europe and the USA. Complete data 
from patient/parent surveys were not available at time of the 
consensus meeting. However, reanalysis of outcomes after 
the close of the patient/parent survey showed that decisions 
made at the consensus meeting still held. Initial response rate 
to Delphi 1 was low (estimated at 26% of potential specialty 
group membership). However, not all members of the respec-
tive organisations contacted would be expected to answer a 
paediatric-specific survey as described previously. Response rates 
and attrition between Delphi 1 and 2 were as expected from 
paediatric rheumatology studies with similar methodology.44–46 
Despite inclusion of neurology and dermatology experts in the 
consensus meeting, the participants of this study were primarily 
rheumatologists.
Considerable discussion took place during the consensus 
meeting regarding the assessment of cutaneous disease in 
myositis. There are many tools available,22 but no single tool 
has been universally accepted. It can be difficult to define skin 
activity versus damage, particularly without a skin biopsy. 
After voting on individual skin items and comparing two tools 
endorsed in JDM, the abbreviated Cutaneous Assessment Tool 
(aCAT) and Disease Activity Score (DAS) skin score,22 agreement 
was reached to use items within the aCAT as disaggregated skin 
manifestations. These items are recognised to reflect cutaneous 
lesions associated with disease activity and damage in juvenile 
and adult myositis.22 Within the item ‘periungual capillary loop 
changes’, ‘measure of nailfold capillary density if available’ 
was added in recognition of nailfold density relating to prog-
nosis.47 48 A direct comparison of all available skin tools was 
outside the remit of this study. Recent published work evalu-
ating the Cutaneous Dermatomyositis Disease Area and Severity 
Index (CDASI) and the Cutaneous Assessment Tool Binary 
Method (CAT-BM) in JDM confirms the reliability of both tools 
when used by paediatric dermatologists or rheumatologists.49
The consensus-driven dataset developed in this study, like 
IMACS and PRINTO core sets, includes physician and patient/
parent global activity, each of which is included in recently 
defined response criteria for minimal, moderate and major 
improvement in JDM.8 IMACS measures muscle strength using 
Manual Muscle Testing, whereas CMAS is used within the 
PRINTO core set. Both were retained in the consensus dataset. 
Both tools have been found to have very good inter-rater reli-
ability (when summary scores are used)22 and either is allowed 
in the recently defined American College of Rheumatology/
European League Against Rheumatism–approved response 
criteria.8 The overlap between the IMACS/PRINTO core sets 
and items contained within the consensus dataset is unsurprising 
as all core sets aim to capture and measure disease activity and 
damage over time. A key difference is that the consensus dataset 
does not use specific tools to record disease activity, such as the 
Myositis Disease Activity Assessment Tool or the DAS, but rather 
uses disaggregated items, each of which has been evaluated by 
a multistage consensus-driven process that considered value 
for both clinical use and research. The dataset was developed 
with a key aim for it to be incorporated into existing registries, 
allowing comparison of data between groups. The already avail-
able web-based Euromyositis registry, www. euromyositis. eu, is 
free to use in clinical practice and for research and includes a 
JDM proforma, which will be modified where needed to include 
items in this new dataset. Likewise, at the time of writing, the 
CARRA Registry is in the final stages of adding JDM (https:// 
carragroup. org/) and will include the items contained in this 
consensus dataset. The JDCBS (h ttps ://www. juveniledermatomy 
osit is. org. uk/) aims to incorporate this dataset as far as possible.
Research priorities defined during the consensus meeting 
included the need to further develop skin assessment tools that 
are practical within a busy clinical setting, develop an abbrevi-
ated muscle assessment tool that removes redundant items from 
a combined Childhood Myositis Assessment Scale and Manual 
Muscle Testing and to further develop PROMs so that they are 
applicable to JDM and acceptable to patients.
COnClusIOn
Through a robust international consensus process, a consensus 
dataset for JDM has been formulated that can capture disease 
activity and damage over time. This dataset can be incorporated 
into national and international collaborative research efforts, 
including existing clinical research databases and used routinely 
while evaluating patients with JDM.
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